Auro-Emtricitabine-Tenofovir · DIN 02490684 · 200mg & 300mg · tablet
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Emtricitabine-Tenofovir · DIN 02490684
Manufacturer: Auro Pharma Inc.; listing date 2023-04-28
Health Canada: Marketed since 2023-03-01 · brand AURO-EMTRICITABINE-TENOFOVIR · ATC J05AR03 TENOFOVIR DISOPROXIL AND EMTRICITABINE · form Tablet · route Oral · ingredients EMTRICITABINE 200 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Auro pharma inc · schedule Prescription
Auro-Emtricitabine-Tenofovir: Formulary list price $7.3035/unit (unit not stated in source; not the patient's cost)
Ministry pays: $7.3035 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98074 · Verify on the e-Formulary ↗ (DIN 02490684)
Source record
DIN 02490684: Auro-Emtricitabine-Tenofovir
Raw flags: sec3=Y
Item: 081800099; group id 84; item number 0152; lccId None; manufacturer id AUR
Source form: Tab; strength: 200mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $7.3035; ministry $7.3035
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490684
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98074
Interchangeable products
AG-Emtricitabine & Tenofovir Disoproxil · DIN 02496356 · $7.3035
Apo-Emtricitabine-Tenofovir · DIN 02452006 · $7.3035
Jamp-Emtricitabine/Tenofovir Disoproxil · DIN 02487012 · $7.3035
Mint-Emtricitabine/Tenofovir · DIN 02521547 · $7.3035
Mylan-Emtricitabine/Tenofovir Disoproxil · DIN 02443902 · $7.3035
PMS-Emtricitabine/Tenofovir · DIN 02461110 · $7.3035
Teva-Emtricitabine/Tenofovir · DIN 02399059 · $7.3035
Truvada · DIN 02274906 · $7.3035
Shortage status: not checked (no credentials)